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SUMMARY 
It is well established that peroxynitrite (PN), formed endogenously by the reaction of nitric 
oxide (NO) and superoxide, largely contributes to the development of myocardial injury, 
resulting from ischaemia and reperfusion (I/R). However, more recent evidence suggests that 
PN in a lower (nanomolar/low micromolar) concentration range, may exert preconditioning 
(PC)-like protective effects. For example, we have shown in a previous study that PN 
administered in 100 nM concentration, markedly reduced the severity of ventricular 
arrhythmias that resulted from acute coronary artery occlusion and reperfusion in 
anaesthetized dogs (Kiss et al., 2008). This study, however, did not examine whether PN, 
generated during the brief periods of preconditioning I/R insults, plays also a trigger role in 
the PC-induced antiarrhythmic protection. Therefore, in the first series of experiments (Study 
I) we examined this by the use of uric acid (UA; 0.2 mg/kg/min, over 30 min), a relatively 
selective scavenger of PN, and the effects obtained in PC dogs were compared to those dogs 
that had been received PN exogenously, 25 min before the occlusion of the left anterior 
descending coronary artery (LAD). In these experiments the severity of ischaemia and of 
ventricular arrhythmias, changes in plasma nitrate/nitrite (NOx) levels, as well as myocardial 
superoxide and nitrotyrosine (NT) production (a marker of PN generation) were assessed.  
We have found that both the PC procedure (2x5 min occlusion/reperfusion) and the 
administration of PN resulted in a significant increase in NT formation, which was abolished 
or markedly attenuated in the presence of UA. This attenuation of PN formation in PC dogs, 
however, did not influence the PC-induced protection; i.e. the number and the incidence of 
ventricular arrhythmias during the prolonged occlusion remained to be suppressed, whereas 
the increase in NO bioavailability and the decrease in superoxide production were as the same 
as in the PC animals. In contrast, UA completely abrogated the protection that resulted from 
the administration of PN. Interestingly, UA itself also reduced the arrhythmias; an effect 
which might be associated with the antioxidant property of the compound. Our conclusion 
was that PN administration results in a PC-like protection against arrhythmias, but PN, 
generated during the PC procedure, is not necessary for triggering the PC-induced 
antiarrhythmic protection. 
The second series of experiments (Study II) aimed to examine whether the increased NO 
bioavailability that occurs in PC dogs, is the direct consequence of an enhanced nitric oxide 
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synthase (NOS) activity or other NO producing mechanisms, such as the non-enzymatic NO 
formation, may also play a role. Therefore, we designed studies in which the time-course 
changes in NOS activity, NO bioavailability, as well as superoxide and NT productions were 
simultaneously examined in control dogs and in dogs subjected to PC. We have found that in 
control dogs subjected to a 25 min LAD occlusion, there was an initial increase in NOS 
activation that occurred around 5 min of the occlusion. Afterwards the enzyme activity 
continuously decreased up to the end of the occlusion period. These changes in NOS activity 
were almost parallel with the alterations in NO levels. In control dogs, there were also marked 
increases in tissue superoxide and NT concentrations, determined at the end of the 25 min of 
the occlusion. In contrast, in dogs subjected to PC the activation of NOS and the production 
of NO were significantly increased during the PC procedure, and these were maintained over 
the entire period of the subsequent prolonged ischaemic insult. Although the PC procedure 
increased the superoxide and NT levels, the generation of these oxidative stress products was 
markedly suppressed during the prolonged occlusion. We concluded from these results that 
PC preserves the NOS enzyme-dependent NO formation, and perhaps through this 
mechanism, it reduces the harmful consequences of the reperfusion-induced oxidative stress. 
We propose that this NOS-dependent increase in NO bioavailability during ischaemia plays a 
mandatory role in the antiarrhythmic effect of PC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
TABLE OF CONTENTS  
 
LIST OF PUBLICATIONS................................................................................................... 2 
SUMMARY ........................................................................................................................... 6 
TABLE OF CONTENTS ...................................................................................................... 8 
LIST OF ABBREVIATIONS .............................................................................................. 10 
1. INTRODUCTION ........................................................................................................... 11 
1.1. The phenomenon of ischaemic preconditioning: from experimental studies to 
clinical exploitation ..................................................................................................... 11 
1.2. The initiation of ischaemic preconditioning: characteristics and possible  
mechanism ................................................................................................................... 12 
1.3. The role of reactive oxygen species (ROS) in ischaemia and reperfusion .................. 15 
1.4. The role of peroxynitrite generation during myocardial ischaemia 
and reperfusion............................................................................................................ 17 
1.5. The source and the role of NO during myocardial ischaemia and reperfusion ......... 18 
AIMS OF STUDY I & STUDY II ....................................................................................... 20 
2. MATERIALS AND METHODS ..................................................................................... 21 
2.1. Ethics statement ........................................................................................................... 21 
2.2. Surgical procedures ...................................................................................................... 21 
2.3.1. Assessment of ventricular arrhythmias ....................................................................... 22 
2.3.2. Assessment of ischaemia severity ................................................................................ 22 
2.4. In vitro measurements  ................................................................................................. 23 
2.4.1. Determination of plasma nitrate/nitrite levels ............................................................ 23 
2.4.2. Assessment of myocardial superoxide (O2
-.
) generation.............................................. 23 
2.4.3. Determination of nitrotyrosine formation................................................................... 24 
2.4.4. Assessment of nitric oxide synthase activity (NOS) .................................................... 24 
2.4.5. Preparation of synthetic peroxynitrite ........................................................................ 24 
2.5. Statistical analysis......................................................................................................... 25 
2.6. Experimental protocols ................................................................................................ 25 
2.6.1. Protocol for Study I..................................................................................................... 25 
2.6.2. Protocol for Study II. .................................................................................................. 26 
3. RESULTS ........................................................................................................................ 28 
3.1. Study I. Evaluation of the trigger role of peroxynitrite in the antiarrhythmic 
effect of ischaemic preconditioning............................................................................. 28 
3.1.1. Haemodynamic effects of pH 8.4 saline, peroxynitrite and urate………… ….………28 
3.1.2. Haemodynamic changes following coronary artery occlusion……………… 28 
3.1.3. The severity of ventricular arrhythmias during a 25 min occlusion of the LAD ........ 30 
3.1.4. Changes in ischaemia severity during a 25 min occlusion of the LAD ...................... 31 
3.1.5. Changes in plasma NOx concentrations during a 25 min occlusion of the LAD ....... 32 
3.1.6. Myocardial superoxide production following a 25 min occlusion and reperfusion .... 33 
3.1.7. Changes in myocardial nitrotyrosine production ........................................................ 34 
3.2. Study II. Examination of changes in NOS activity during myocardial ischaemia ..... 35 
3.2.1. NOS enzyme activity following PC and a prolonged period of LAD occlusion........... 35 
3.2.2. Changes in plasma nitrate/nitrite (NOx) levels following preconditioning 
and during sustained ischaemia........................... .... .................................................... 36 
9 
 
 
 
3.2.3. Changes in myocardial superoxide production following the PC procedure and    
during a 25 min LAD occlusion...................................................................................... 37 
3.2.4. Changes in nitrotyrosine formation in control and preconditioned dogs.................... 38 
4. DISCUSSION .................................................................................................................. 39 
New findings ........................................................................................................................ 39 
5. REFERENCES ................................................................................................................ 48 
ANNEX ................................................................................................................................ 65 
AKNOWLEDGEMENTS ................................................................................................... 66 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
 
LIST OF ABBREVIATIONS 
 
5-HD: 5-hydroxydecanoate 
AU: arbitrary units 
BH4: tetrahydrobiopterin 
BK: bradykinin 
cGC: soluble guanylyl cyclase 
DABP: diastolic arterial blood pressure 
DHE: dihydroethidine  
EDTA: Ethylenediaminetetraacetic acid 
ERK: extracellular signal-regulated kinase    
eNOS: endothelial nitric oxide synthase 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HR: heart rate 
iNOS: inducible nitric oxide synthase 
I/R: ischaemia and reperfusion  
LAD: left anterior descending coronary artery 
L-NAME: L-NG-nitroarginine methyl ester   
LVEDP: left ventricular end-diastolic pressure 
LVSP: left ventricular systolic pressure 
MABP: mean arterial blood pressure 
mitoKATP: mitochondrial ATP-sensitive potassium channels  
NAC: N-acetyl-L-cysteine 
NADPH: nicotinamide adenine dinucleotide phosphate  
NaNO2: sodium nitrite 
NaNO3: sodium nitrate 
NO: nitric oxide 
NOS: nitric oxide synthase  
nNOS: neuronal nitric oxide synthase 
NOx: nitrate/nitrite 
O2
-.
: superoxide 
p38MAPK: p38 mitogen activated protein kinase 
PBS: phosphate buffer solution 
PKC: protein kinase C 
PN: peroxynitrite 
ROS: Reactive oxygen species 
SABP: systolic arterial blood pressure  
UA: uric acid, urate  
VF: ventricular fibrillation  
VPBs: ventricular premature beats 
VT: ventricular tachycardia 
WHO: World Health Organization 
 
11 
 
 
1. INTRODUCTION 
The reduced blood supply to the myocardium, resulting from coronary artery occlusion causes 
ischaemic changes that are often accompanied by the occurrence of lethal ventricular 
arrhythmias. According to the statistic of the World Health Organization (WHO), both in men 
and women the ischaemia-induced sudden cardiac death results in more than 7 million deaths 
per year in the world (Finegold et al., 2013). Consequently, the search for novel strategies, 
which aim to prevent or reduce the acute ischaemia and reperfusion (I/R)-induced life-
threatening arrhythmias is still a major challenge in both the experimental and clinical 
cardiology. Such a novel strategy might be the phenomenon of ischaemic preconditioning 
(Murry et al., 1986). 
1.1. The phenomenon of ischaemic preconditioning: from experimental studies to clinical 
exploitation   
It is now 28 years that PC, as one of the endogenous adaptive phenomena, was first described 
by Murry and colleagues (1986) in anaesthetized dogs. They showed that four 5 min periods 
of occlusion of the left circumflex coronary artery 5 min prior to a 40 min occlusion of the 
same artery markedly reduced the size of the infarct, the myocardial ATP consumption and the 
drop in pH (Murry et al., 1986). Since then the protective effects of PC have been described 
and confirmed in various experimental settings. It was shown that PC markedly reduces the 
severity of ischaemia and reperfusion-induced ventricular arrhythmias (Shiki and Hearse, 
1987; Végh et al. 1990, 1992a) and improves the restoration of contractile dysfunction 
following reperfusion (Cave and Hearse, 1992; Hendrikx et al., 1993). Somewhat later it was 
also turned out that not only the brief periods of I/R insults, but other stimuli, such as cardiac 
pacing (Végh et al., 1991a), heavy physical exercise (Babai et al., 2002), heat stress 
(Cumming et al., 1996), an increase in myocardial stretch (Ovize et al., 1994), as well as 
various pharmacological agents (Cohen et al., 2000) can induce a PC-like protection. 
It was also an early recognition that PC is a general phenomenon; the protection can be 
initiated in all species thus far investigated, including humans (Tomai et al., 1994; Arstall et 
al., 1998), suggesting a possibility for clinical exploitation of the phenomenon. Another 
important aspect of PC is that the protection is time dependent; it occurs in two distinct 
phases. There is an ‘early phase’ which appears immediately after the PC stimulus, but it 
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fades within 1 or 2 hours (Végh et al., 1992a). However, the protection reappears 20-24h later 
(Marber et al., 1993; Kuzuya et al., 1993; Végh et al., 1994a), and this phase is termed as late 
or delayed or “second window of protection” (Szekeres et al., 1989; Yellon and Baxter, 1995). 
Of particular importance, the PC phenomenon can occur in humans as well (Schwarz et al., 
1999). The first evidence for this was provided by Deutsch et al. (1990). They showed that in 
patients with coronary artery disease, and undergoing percutaneous transluminal coronary 
angioplasty, the repeated balloon inflations resulted in less marked ST-segment changes and 
increases in lactate levels (Deutsch et al., 1990). Similarly, the TIMI studies indicated that the 
clinical outcome of myocardial infarction is better in those patients, who suffered from 
preinfarct angina within 24 hours of the onset of the infarction (Kloner et al., 1995, 1998). 
Similarly, in patients undergoing coronary artery bypass grafting, the intermittent aortic cross-
clamping procedure (2-times for 3 min with 2 min reperfusion intervals) prior to a 10 min 
global ischaemia, preserved ATP levels and reduced myocardial injury, as assessed by a lower 
troponin T release (Yellon et al., 1993; Jenkins et al., 1997). Also, human studies have 
revealed that PC reduced the infarct size (Ottani et al., 1995), lowered creatine kinase values 
(Kloner et al., 1998), ameliorated the ejection fraction, preserved contractile function 
(Nakagawa et al., 1995; Napoli et al., 1998), enhanced the development of new collaterals and 
suppressed the occurrence of tachyarrhythmias (Tamura et al., 1997). A novel promising 
clinical exploitation of PC is proposed in relation to heart transplantation by the preservation 
of the donor heart (Karck et al., 1996). 
1.2. Initiation of ischaemic preconditioning: characteristics and possible mechanism  
Despite of the intensive research, several key questions have still remained to be unanswered 
as regards the molecular and cellular mechanisms of PC. As mentioned above, the 
phenomenon was first described in anaesthetized dogs (Murry et al., 1986), but it has turned 
out soon that a similar protection can also be induced in other species, such as in swine 
(Schott et al., 1990), rabbit (Cohen et al., 1991), rat (Li and Kloner, 1992), sheep (Burns et al., 
1995) and in mouse (Sumeray and Yellon, 1998). It is a common feature of the PC-induced 
adaptation that the stimulus should be reached a threshold to elicit protection, although this 
threshold might be different in the various species. The development of protection is 
dependent on the strength of the PC stimulus, which can be modified by the duration and/or 
the number of the PC cycles. The strength of the stimulus may also be different for the 
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experimental end-points examined (Li et al., 1990; Van Winkle et al., 1991; Miura et al., 
1992; Végh et al., 1992a; Seyfarth et al., 1994; Barbosa et al., 1996; Schulz et al., 1998). For 
example, in dogs one or two cycles of 5 min PC occlusion resulted in almost similar 
antiarrhythmic protection, whereas in rats the optimal stimulus to achieve protection against 
arrhythmias was 3 min (Végh et al., 1992a). In case of the examinations of infarct size, there 
were no differences between a single 5 min ischaemia and 6 or 12 cycles in the canine (Li et 
al., 1990). In rabbits, one single 2 min period of occlusion was ineffective to induce 
protection, but two 2 min occlusions resulted in similar reduction in infarct size than a single 
5 min occlusion (Miura and Iimura, 1993). 
It is now also well established that PC induces the formation and release of several 
endogenous substances from the heart, which may have either beneficial or deleterious effects 
on the cardiovascular system (Curtis et al., 1993; Parratt, 1993; Cohen et al., 2000; Downey et 
al., 2007). It is proposed that these substances, via receptor-dependent and receptor-
independent mechanisms, may activate various signalling pathways and modify end-effectors 
(one or more), leading ultimately to cardioprotection (Downey et al., 2007). The first 
endogenous substances that were associated with the PC-induced cardioprotection, were 
prostacyclin (Végh et al., 1990), bradykinin (Végh et al., 1991b), and adenosine (Liu et al., 
1991). For example, Downey and colleagues showed that adenosine is released during the 
short periods of I/R insults (Liu et al., 1991), and by acting on the Gi-coupled A1 receptor, 
stimulates the translocation of protein kinase C (PKC) from the cytosol to the membrane 
(Cohen et al., 2000). Furthermore, the blockade of A1 receptors abolished, whereas the 
administration of A1 agonist mimicked the cardioprotective effects of PC (Liu et al., 1991; 
Thornton et al., 1992). Parallel with this adenosine hypothesis, our research group proposed 
that bradykinin (BK), formed rapidly after the onset of ischaemia, plays also an important 
trigger role in the antiarrhythmic effect of PC (Végh et al., 1991b, 1993; 1994b). The 
administration of BK (Végh et al., 1991b) and the combined ACE/NEP inhibitor Z13752A, 
which increases endogenous BK levels by inhibiting the degradation of BK (Rastegar et al., 
2000) mimicked, whereas the blockade of BK2 receptors with icatibant markedly attenuated 
the antiarrhythmic effect of PC (Végh et al., 1994b). Furthermore, it was suggested that BK, 
by activating B2 receptors, stimulates the generation and the release of nitric oxide (NO) from 
the endothelium, and possibly also from cardiac myocytes, since the protective effect of BK 
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was abolished by the NOS inhibitor L-NAME (Végh et al., 1993). 
There is now substantial evidence that NO plays an essential role in the cardioprotective 
effect of PC (Végh et al., 1992b; Bilinska et al., 1996; Lochner et al., 2000). The first 
evidence for this came from studies in anaesthetized dogs which showed that the 
antiarrhythmic effect of PC was abolished by the administration of the nitric oxide synthase 
(NOS) enzyme inhibitor, L-NAME (Végh et al., 1992b). It was proposed that in 
antiarrhythmic effect of PC, the activation of the BK-NO-soluble guanylyl cyclase (sGC) 
pathway and the resulting increase in cGMP, plays a mandatory role (Végh et al., 1994a; 
Végh and Parratt, 1996), since the administration of methylene blue, a non-selective inhibitor 
of sGC, completely abolished the protection against arrhythmias, resulting from PC (Végh et 
al. 1992c). There are many ways by which cGMP can lead to cardioprotection; e.g. it activates 
the cGMP-dependent phosphodiesterase enzyme, which reduces cAMP and thereby the influx 
of calcium through the L-type calcium channels (Parratt and Végh, 1996), or it stimulates 
protein kinase G (PKG) and opens mitochondrial ATP-sensitive potassium channels 
(Oldenburg et al., 2004; Costa et al., 2005), etc. Indeed, closing of mitoKATP-channels with 5-
hydroxydecanoate (5-HD), attenuated the PC-induced antiarrhythmic protection (Végh and 
Parratt, 2002). Both mechanisms (reduction in calcium influx and opening of mitoKATP 
channels) during ischaemia may have a protective role against the generation of arrhythmias. 
There are, of course, several other substances, such as angiotensin II (Liu et al., 1995), 
endothelin-1 (Wang et al., 1996) and opioids (acting mainly on κ and/or δ opioid receptors; 
Miki et al., 1998), which have also been proposed to participate in the initiation of PC. Their 
role, however, in the PC-induced cardioprotection is not well established and, indeed, seems 
rather controversial (Miki et al., 1998; Dickson et al., 2001; Weinbrenner et al., 2002). For 
example, the AT2 and ET1 receptor blockers failed to inhibit the angiotensin II and 
endothelin-induced protection (Sharma and Sing, 1999; Erikson et al., 1996), indicating that 
these substances may have a negligible role in the PC-induced cardioprotection. 
Substances that are generated mainly during reperfusion, and are thought to play an important 
role in I/R injury, such as, for example, superoxide and peroxynitrite, have also been proposed 
to play a trigger role in PC (Baines et al., 1997; Altug et al., 2000, 2001).  Their importance, 
as triggers of the PC-induced protection is discussed in sections 1.3 and 1.4. 
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It might well be that several substances (protective and deleterious) are released from the 
myocardium during the brief transient ischaemia and reperfusion insults, and contribute to the 
protection afforded by PC (Parratt, 1993). For example, according to the concept of Downey 
and colleagues, the release of these endogenous substances depends on the strength of the PC 
stimulus, i.e. the stimulus should reach a threshold to induce the release of a certain substance 
(Goto et al., 1995). Thus, if a stimulus is adequately strong (i.e. reaches the threshold of the 
release of many substances), then the inhibition of the release of one of the substances would 
not result in the abolition of the protection, since the other substances that are also released by 
this stimulus, are still able to evoke the protection (Cohen et al., 2000).     
In summary, it seems more than likely that the short periods of ischaemia and reperfusion 
insults initiate the formation and the release of several endogenous substances. Some of them 
might be protective, whereas the others might be potentially injurious. It might well be that 
these substances are acting in concert to trigger and mediate the protection. Our work, 
described in the first part of the present thesis, focused on the further examination of those 
endogenous substances, namely nitric oxide, superoxide and peroxynitrite, which have 
already known to be formed and released during preconditioning and are thought to play a 
role in cardioprotection associated with PC. 
1.3. The role of reactive oxygen species (ROS) in ischaemia and reperfusion  
There is no doubt that reactive oxygen species (ROS) play a substantial role in ischaemia and 
reperfusion injury (Simpson and Lucchesi 1987; Zweier et al., 1987; Ferrari et al., 1989, 
1991; Richard et al., 1990). It has been shown that a burst of ROS that occurs mainly during 
reperfusion provokes serious ventricular arrhythmias and contributes to further injury of 
myocardial cells (Kloner et al., 1989; Giordano 2005). Several sources of ROS were 
identified in the heart, but it is still a matter of debate what is the major source of these 
oxygen products during myocardial ischaemia. Besides the mitochondria, which is one of the 
main sources of ROS formation, NAD(P)H oxidases, cytochrome P-450, xanthine 
oxidoreductases, auto-oxidation of catecholamines, etc. are candidates for ROS generation. 
Within the mitochondria, the elements of the electron transport chain (complex I and III), 
monoamine oxidases, phosphorylated p66
shc 
protein, NADPH oxidase 4 might be the sources 
of intracellular ROS production (Kloner et al., 1989; Giordano 2005; DiLisa et al., 2009). 
Under aerobic conditions, ROS is eliminated by the endogenous antioxidants, such as 
16 
 
 
superoxide dismutase, urate, glutathione and catalase, but since under ischaemic conditions 
the antioxidant defence system is also injured, an imbalance develops between the capacity of 
the antioxidants and the generation of ROS. Interestingly, the increase of antioxidant capacity, 
for example by the combined administration of two antioxidants (i.e. superoxide dismutase 
and catalase) reduced the reperfusion-induced injury (Jolly et al., 1984).  
As regards the deleterious effects of oxygen radicals in arrhythmia point of view, it is 
suggested that ROS is involved in the generation of early and delayed afterdepolarizations, 
and causes action potential abnormalities by influencing the function of various ion channels 
(e.g. late Na
+
, L-type Ca
2+
and K
+
 channels), ion transporters (e.g. Na/Ca exchanger), as well 
as the activity of enzymes, such as Ca/calmodulin kinase (Xie et al., 2009). The oxidation of 
ion channel subunits by ROS (e.g. L-type Ca
2+
 channel α1 subunit) is suggested to contribute 
to the action potential abnormalities and S-nitrosylation, a posttranslational protein 
modification of sulfhydryl residues by NO prevented the ROS-induced oxidative modification 
of channel subunits (Sun et al., 2006a, 2006b). 
There is also evidence that ROS by opening of mitochondrial permeability transition pore is 
involved in the apoptotic and necrotic cell death (Hausenloy et al., 2002). 
On the other hand, ROS, generated after the short episodes of ischaemia (i.e. during PC), is 
thought to play a trigger role in the cardioprotective effect of PC (Baines et al., 1997). The 
evidence for this came from studies which showed that scavenging ROS during the PC 
procedure attenuated the protective effects of PC, whereas the enhancement of ROS formation 
induced a PC-like cardioprotective effects (Tritto et al., 1997). Although the precise 
mechanisms by which ROS induces protection is still not clear, a role for PKC-mediated 
pathway (Von Ruecker et al., 1989; Gopalakrishna et al., 1989) and for the modulation of 
mitoKATP channels (Zhang et al., 2001; Lebuffe et al., 2003) are suggested. It is proposed that 
ROS generated during PC, results from mitochondrial sources, i.e. the opening of mitoKATP 
channels enhances the mitochondrial ROS formation. This, through the activation various 
kinases and survival signalling pathways, such as ERK pathway would result in protection by 
reducing ROS generated during the prolonged ischaemia and reperfusion insult (Yue et al., 
2000; Hausenloy et al., 2004, 2005; Yang et al., 2010). ERK can also phosphorylate 
connexin43 resulting in reduction in gap junction permeability (Naitoh et al., 2006). Opening 
these channels may also lead to the inhibition of mitochondrial calcium overload (O’Rourke 
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et al., 2000) and they are involved in the regulation of mitochondrial volume by ameliorating 
energy transfer between mitochondria and cellular ATP-ases (Kowaltowski et al., 2001). 
 
1.4. The role of peroxynitrite generation during myocardial ischaemia and reperfusion 
Wang and colleagues reported that during early reperfusion, there is a simultaneous elevation 
in NO and ROS production, and that these radicals react, by nearly a diffusion-limited rate, to 
produce another potent oxidant, peroxynitrite (PN; Wang et al., 1996; Wang and Zweier, 
1996). This non-radical molecule PN may have both deleterious and beneficial effects, 
depending largely on its concentration (Yasmin et al., 1997; Ferdinandy and Schultz, 2001, 
Ferdinandy, 2006). For instance, high concentration (>20 µM) of PN, formed either 
endogenously or administered exogenously, results in endothelial dysfunction (Zou et al., 
2004), contributes to cell necrosis (Virág et al., 1998), induces the breakage of DNA (Virág et 
al., 2003) and may provoke cardiac arrhythmias (Tecder-Unal and Kanzyk, 2004). The 
underlying mechanisms of the cytotoxic effects of PN could be associated with the oxidation 
of lipids and proteins, in which the modification of protein tyrosine residues by nitration may 
play an important role (Yasmin et al., 1997). 
There is, however, increasing evidence that PN, in low (nanomolar) concentrations, can elicit 
protective effects in the heart. It has been shown that PN preserves endothelium function via 
the inhibition of leukocyte-endothelial cell interaction (Nossuli et al., 1997), reduces platelet 
aggregation (Lefer et al., 1997), produces coronary vasodilatation (Liu et al., 1994), and 
decreases infarct size following I/R (Nossuli et al., 1997). The proposed mechanisms include 
(i) the formation of S-nitrosothiols and the subsequent NOS-independent NO release (Wu et 
al., 1994), (ii) the activation of soluble guanylate cyclase and the subsequent increase in 
cGMP (Al-Sa'doni  and Ferro, 2000), as well as (iii) the activation of various protein kinases, 
such as PKC, ERK and p38MAPK  (Agbani et al., 2011).    
There is also evidence that PN is generated during the PC procedure and may play a trigger 
role in the antiarrhythmic effect of PC (Altug et al., 2000, 2001). In rat isolated hearts the 
inhibition of PN formation by the administration of uric acid (UA) during PC markedly 
attenuated the antiarrhythmic effect of PC (Altug et al., 2000, 2001). Similarly, the protection 
resulted from the exogenous administration of PN was abolished in the presence of UA (Altug 
et al., 2000, 2001). In our own experiments using anaesthetized dogs we showed that PN 
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infused directly into the coronary circulation in a concentration of 100 nM, significantly 
reduced the severity of ventricular arrhythmias that resulted from a 25 min coronary artery 
occlusion and reperfusion insult (Kiss et al., 2008). This protection was similar to that seen 
with ischaemic PC (Kiss et al., 2008, 2010), or after the administration of NO donors (Végh et 
al., 1996; György et al., 2000; Gönczi et al., 2009). The fact that PN administration results in 
an antiarrhythmic effect raised the question whether in this large animal arrhythmia model the 
endogenously formed PN would contribute to the PC-induced antiarrhythmic protection. 
1.5. The source and the role of NO during myocardial ischaemia and reperfusion 
The first evidence that NO may play a role in the cardioprotective effect of PC came from 
those dog studies in which we showed that inhibition of the L-arginine-NO synthesis pathway, 
abolishes the protective effect of PC against arrhythmias (Végh et al., 1992b). Although it is 
still not quite clear how PC stimulates the generation and release of NO, it was proposed that 
the stress stimulus-induced rapid BK formation and the subsequent release of NO from the 
endothelium may play a role (Végh et al., 1993; Parratt and Végh, 1996). In the meantime it 
was reported that chronic exercise in dogs increases coronary vascular nitric oxide production 
and endothelial nitric oxide synthase (eNOS) gene expression (Sessa et al., 1994), suggesting 
a BK-independent pathway for NO formation. More recently the PI3/Akt pathway is proposed 
to play an important role in the rapid activation of eNOS (Fulton et al., 1999).  
According to our best knowledge, there are, at least, three isoforms of NOS enzyme, which 
synthesize NO: the endothelial (eNOS), neuronal (nNOS) and the inducible (iNOS) forms. 
These are different in their amino acid sequence, cellular localization, inhibitors and calcium 
dependency (Förstermann et al., 1994). More recently, it has also become evident that there 
are possibilities for enzyme-independent NO production as well (Kuppusamy et al., 2001), 
which occur mainly under ischaemic conditions (Zweier et al., 1995 a,b). In isolated heart 
preparations, using electron paramagnetic resonance for NO measurement, a considerable 
increase in NO production was detected (Zweier et al., 1995a), suggesting that during 
ischaemia NO is preferably generated from nitrite, rather than synthesized by NOS. This 
excess in NO formation would be detrimental, since NO, by reacting with superoxide, 
promotes the formation of toxic peroxynitrite. This can be especially detrimental during 
reperfusion, when a burst of superoxide occurs. According to this hypothesis, the reduction of 
NO generation would result in protection. Indeed, there is some evidence that in the rat 
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isolated hearts, PC reduced the generation of NO and that this reduced NO was associated 
with cardioprotection (Csonka et al., 1999). These in vitro studies were, however, not 
supported by the results of the in vivo experiments. In these studies, measuring tissue NO 
availability in the interstitial fluid by microdialysis (Mori et al., 1998; Stevens et al., 2002) or 
by electrochemical techniques (Engelman et al., 1995; Prasan et al., 2007), a reduced NO 
formation was found during myocardial ischaemia (Stevens et al., 2002; Prasan et al., 2007). 
In our own experiments, where the plasma nitrate/nitrite (NOx) levels in the blood of the 
coronary sinus and the generation of superoxide and nitrotyrosine (a biomarker of PN) in 
myocardial tissue samples were simultaneously measured, we showed that in dogs subjected 
to a 25 min occlusion/reperfusion insult, the plasma NOx levels were significantly elevated at 
the beginning (around 7 min) of the occlusion, but after that the NOx levels started to 
markedly decline (Kiss et al., 2010). Reperfusion of the ischaemic myocardium in these dogs 
resulted in marked increases in superoxide and NT levels, which almost certainly largerly 
contributed to a marked increase in the reperfusion-induced fatal ventricular arrhythmias 
(Kiss et al., 2010). In contrast, in dogs subjected to PC the plasma NOx levels were elevated, 
and this increased NO bioavailability was present over the entire prolonged period of 
occlusion (Kiss et al., 2010). Moreover, PC reduced the increased superoxide and NT 
formation that resulted from the combined ischaemia and reperfusion insult. On the basis of 
these results we proposed that the preservation of NO bioavailability during ischaemia may 
have an influence on the generation of superoxide and peroxynitrite during reperfusion and 
this mechanism has a role in the marked antiarrhythmic effect of PC (Kiss et al., 2010). 
Indeed, there are studies which show that NO regulates mitochondrial superoxide production 
(Burwell and Brookes, 2008), and that protects the myocardium against reperfusion injury via 
protein S-nitrosylation (Kohr et al., 2011). 
Although it seems more than likely that PC may influence NOS activity (Xuan et al., 2000) 
and expression (Sessa et al., 1994; Kovács et al., 2010), there is a lack of evidence whether 
the preservation of NO bioavailability following PC results from the influence of the PC 
stimulus on the enzyme-dependent or/and an enzyme-independent NO formation. It is also not 
well established, what is the time-course changes in the generation of other substances, 
namely superoxide and peroxynitrite, which can also be generated during the PC stimulus, 
and which formation is modified by NO.  
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AIMS 
The aims of studies, involved in the present Thesis were as follows: 
STUDY I.  
On the basis of our own and others previous studies (Altug et al., 2000, 2001; Kiss et al., 
2008, 2010), we hypothesized that peroxynitrite (PN) is produced during the PC stimulus, and 
it may act as a trigger for the PC-induced antiarrhythmic protection. To examine this we 
designed experiments in which uric acid (UA), a relatively selective scavenger of PN, was 
administered in dogs subjected to PC, and the results were compared to those that had been 
obtained in dogs treated with 100 nM concentration of PN. Urate was given in intravenous 
infusion in a dose of 0.2 mg/kg/min, both 10 min prior to and during PC procedure (total 
duration is 20 min), as well as together with the intracoronary administration of the 100 nM 
concentration of PN. 
STUDY II. 
The experiments involved in this part of the Thesis aimed to examine whether the PC-induced 
preservation in NO bioavailability during prolonged ischaemia is due to changes in NOS 
enzyme activity, or other enzyme-independent NO formation may also play a role. To achieve 
this aim, we assessed the time-course changes in NOS activation in parallel with alterations in 
plasma NOx levels, tissue superoxide and nitrotyrosine production in control dogs (without 
PC), and  in dogs that were subjected to PC by two 5 min occlusion and reperfusion insults 5 
min prior to a 25 min occlusion of the LAD. 
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2. MATERIALS AND METHODS  
Since in Study I and Study II the experimental procedures, the measured parameters and 
methods for the in vivo and in vitro measurements were identical, these sections are valid for 
both studies, and only the ‘Experimental protocols’ are described separately. 
2.1. Ethics statement 
The origin and upkeep of these dogs were in accord with Hungarian law (XXVIII, chapter IV, 
paragraph 31) regarding large experimental animals, which conforms with the Guide for the 
Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No. 85-23, revised 1996), and conformed to the Directive 2010/63/EU of the 
European Parliament. The protocols have been approved by the Ethical Committee for the 
Protection of Animals in Research of the University of Szeged, Szeged, Hungary (approval 
number: I-74-5-2012) and by the Department of Animal Health and Food Control of the 
Ministry of Agriculture and Rural Development (authority approval number XIII/1211/2012). 
2.2. Surgical procedures 
Inbred adult mongrel dogs of either sex, and with a mean body weight of 19 ± 5 kg (Study I) 
and 18 ± 4 (Study II) were anaesthetized with an intravenous bolus injection of 
pentobarbitone (0.5 mg kg
-1
 i.v., Euthanyl
®
 Bimeda-MTC Animal Health Inc.) and all efforts 
were made to minimize suffering. Prior to the studies the dogs were housed in an animal room 
(temperature: 10-20 
o
C, humidity: 40-70%, lightening: 12 h per day, 2 animals per pen), for at 
least two weeks and fed a standard diet with ad libitum access to water. Food was withdrawn 
24 h before anaesthesia.   
After catheterization of the right femoral vein, the anaesthesia was maintained with the 
intravenous administration of a mixture of chloralose and urethane (60 and 200 mg kg
-1
, 
respectively; Sigma, St. Louis, MO, USA). The depth of anaesthesia was monitored by the 
examination of the cornea and pain reflexes as well as by the measurement of blood pressure, 
and when it was necessary, a further bolus injection of the anaesthetic was given. The dogs 
were ventilated with room air using a Harvard respirator at a rate and volume sufficient to 
maintain arterial blood gases within normal limits (Végh et al., 1992a). Body temperature was 
measured from the mid-oesophagus and maintained at 37  0.5 
o
C.  
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Polyethylene catheters (Cordis F4) were introduced into the right femoral artery for 
monitoring arterial blood pressure (systolic, diastolic and mean), and into the left ventricle 
(LV), via the left carotid artery, for the measurement of LV systolic and end-diastolic 
(LVEDP) pressures and LVdP/dt (isovolumic contraction and relaxation). All these parameters 
together with a chest lead electrocardiogram were measured with a Plugsys Hemodynamic 
Apparatus (Hugo Sachs Electronics, Germany) and recorded on a Graphtec Thermal Array 
Recorder (Hugo Sachs Electronics, Germany).  
A thoracotomy was performed at the left fifth intercostal space and the anterior descending 
branch of the left coronary artery (LAD) prepared for occlusion just proximal to the first main 
diagonal branch. Distal to the occlusion site, a small side branch of the same artery was also 
prepared and cannulated for the administration of peroxynitrite or saline. Through the right 
jugular vein a catheter was positioned into the coronary sinus to collect blood samples for the 
measurement of plasma nitrate/nitrite (NOx). The left jugular vein was also catheterized for 
the intravenous infusion of uric acid (UA).  
2.3.1. Assessment of ventricular arrhythmias  
The number and severity of ventricular arrhythmias were assessed from the chest lead II 
electrocardiogram, according the Lambeth conventions (Walker et al., 1988), modified by us 
as described elsewhere (Végh et al., 1992a). Thus, the total number of ventricular premature 
beats (VPBs), the incidence and the number of episodes of ventricular tachycardia (VT; 
defined as a run of four or more VPBs at a rate faster than the resting sinus rate), and the 
incidence of ventricular fibrillation (VF) were assessed during the occlusion period. During 
reperfusion, only the incidence of VF (which is a final event in this species) was determined. 
Dogs that were still alive 2 min after reperfusion (the end of the study) were considered to be 
survivors.  
2.3.2. Assessment of ischaemia severity 
The severity of myocardial ischaemia was evaluated by two parameters; changes in the 
epicardial ST-segment and in the degree of inhomogeneity of electrical activation. These were 
measured by means of a composite electrode positioned within the potential ischaemic area of 
the left ventricular wall. This electrode gives a summarised recording of R waves from 24 
epicardial measuring points as described previously (Végh et. al., 1992a). Under normal 
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myocardial perfusion and oxygenation, all sites are activated simultaneously, resulting in a 
single large spike. However, following occlusion, widening and fractionation of this 
summarized R-wave occurs, indicating that the adjacent fibres are not simultaneously 
activated because of the inhomogeneity of conduction. The greatest delay in activation 
occurring within the ischaemic area following coronary artery occlusion was expressed in ms. 
The composite electrode also contains four unipolar electrodes by which changes in epicardial 
ST-segment were evaluated (in mV) within the ischaemic zone. 
2.4. In vitro measurements 
2.4.1. Determination of plasma nitrate/nitrite levels 
Plasma nitrate/nitrite (NOx) levels were measured by Griess reaction as outlined by Moshage 
et al., (1995). Blood samples, collected from the coronary sinus at different time points 
(Figure 1 and 2.) were centrifuged at 10 000 g for 15 min at 4°C. The plasma was mixed with 
β-nicotinamide adenine dinucleotide phosphate (NADPH), flavin adenine dinucleotide, nitrate 
reductase (Sigma, MO) and incubated for 30 min at 37°C. After the enzymatic conversion of 
nitrate to nitrite, the mixture was incubated with Griess reagent for further 10 min at room 
temperature. The absorbance of the azo compound was measured spectrophotometrically at a 
wavelength of 540 nm and the total nitrate/nitrite (NOx) concentration (µmol/L) was assessed 
using a standard calibration curve of sodium nitrite (NaNO2, MO) and sodium nitrate (NaNO3, 
Sigma, MO). 
2.4.2. Assessment of myocardial superoxide (O2
-.
) generation 
This was determined using dihydroethidine (DHE) fluorescent dye method. DHE enters freely 
into the cell and is oxidized by superoxide to yield fluorescent ethidium, which binds to DNA 
(Eth-DNA). Tissue blocks (0.5 x 0.5 x 2 cm) were excised from the ischaemic area and 
embedded in optical cutting temperature compounds. These samples were cut into 20 µm 
cryosections and stained with DHE (1µM) dissolved in phosphate buffer solution (PBS; pH 
7.4), and incubated at 37 °C for 30 min in a dark humidified chamber. Samples, where the 
reaction was blocked with a thiol-containing antioxidant, N-acetyl-L-cysteine (100 mM, 
Sigma, St Louis, MO, U.S.A), served as a negative controls. Both from the stained and 
negative control samples 10 to 15 serial images were captured by a confocal laser scanning 
microscope (Olympus FV1000). The intensity of the fluorescent signals were analysed by 
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ImageJ software (NIH, Bethesda, MD) and expressed in arbitrary units (AU).  
2.4.3. Determination of nitrotyrosine formation 
Myocardial nitrotyrosine (NT), a biomarker of peroxynitrite (PN) formation was evaluated by 
Western blot. Tissue samples were taken from the ischaemic area within two minutes of the 
reperfusion as described previously (Kiss et al., 2008). To assess tyrosine nitrosylation, 20 µg 
of total protein was separated on 8% polyacrylamide gel and the protein bands were 
transferred to polyvinylidene membrane (100 V, 400 mA, for 120 min). After blocking in 5% 
non-fat milk, the membrane was incubated with mouse monoclonal anti-nitrotyrosine 
antibody (in a dilution of 1:1000; MAB5404, Chemicon, Millipore Corp., Billerica, MA, 
USA), and then with horseradish peroxidase-conjugated rabbit anti-mouse IgG (in a dilution 
of 1:1000, P0161, Dakocytomation A/S, Glostrup, Denmark) as a secondary antibody. For 
visualisation, the membrane was developed with an enhanced chemiluminescence kit (ECL 
Plus, GE Healthcare, Little Chalfont, Buckinghamshire, UK), exposed to X-ray film and 
scanned. The intensity of bands was determined using ImageJ software (NIH Bethesda, MD), 
and expressed in percentage of the sham-operated dogs. Equal protein loading was confirmed 
by monitoring GAPDH.   
2.4.4. Assessment of nitric oxide synthase activity (NOS)  
In Study II this was performed using a NOS assay kit (Cayman Chemical, Ann Arbor, MI, 
USA) according to the manufacturer’s instructions. This method is based on the biochemical 
conversion of [
3
H] L-arginine to [
3
H] L-citrulline by NOS. From the tissue samples (100 mg) 
proteins were isolated, homogenized in ice-cold homogenization buffer (Cayman Chemical, 
Ann Arbor, MI, USA), and centrifuged at 10000 g for 15 min, at 4 °C. The supernatant was 
added to the reaction mixture and incubated for 60 min at room temperature. A liquid 
scintillation counter (Wizard
TM
, USA) was used to determine total NOS activity by measuring 
the amount of the radio-labelled citrulline formed during the reaction, and expressed as the 
percentage of the total counts corrected with the background counts per minute.  
2.4.5. Preparation of synthetic peroxynitrite 
For the experiments in Study I. peroxynitrite was synthesized at the Department of 
Biochemistry (University of Szeged, Hungary) according to the method of Beckman and 
colleagues (Beckman et al., 1994), from acidified nitrite and hydrogen peroxide (Kiss et al., 
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2008). The absorbance of synthesized PN was evaluated spectrophotometrically at 302 nm 
wavelength. Stock solutions (50-150 mM) were stored in Eppendorf tubes wrapped in 
aluminium foil at -80 °C. Before use in each experiment, the concentrations were evaluated 
and then diluted to 100 nM with appropriate volume of pH 8.4 saline (Nossuli et al., 1997). 
2.5. Statistical analysis 
Data analysis was performed using STATISTICA software (Statsoft, Oklahoma, USA). All 
values are expressed as means ± s.e. mean and differences between means compared by 
ANOVA for repeated measures or by one-way ANOVA as appropriate, using the Fisher post 
hoc test. Ventricular premature beats and episodes of ventricular tachycardia were compared 
using the Kruskal-Wallis test. The incidence of arrhythmias (such as VT and VF) and survival 
from the combined ischaemia and reperfusion insult was compared by the Fisher Exact test. 
Differences were considered significant at P<0.05.  
2.6. Experimental protocols 
2.6.1. Protocol for Study I. This is shown in Figure 1. The dogs were randomly divided into 
eleven groups. After completing the surgical preparations, a 20 min recovery period was 
allowed to stabilise the haemodynamic and blood gas parameters. In all groups, myocardial 
ischaemia was induced by a 25 min occlusion of LAD followed by rapid reperfusion. In the 
preconditioned dogs this was preceded by two 5 min periods of LAD occlusion either in the 
absence (PC; n=10) or in the presence of urate (UA+PC; n=8). Urate was infused 
intravenously into the jugular vein in a dose of 0.2 mg/kg/min, over 30 min before the 
sustained ischaemic period. In further two groups, synthetic PN, dissolved in pH 8.4 saline, 
was given in a concentration of 100 nM in intracoronary infusion (rate: 0.5 ml/min) for 
identical periods to the PC occlusions, either with (UA+PN; n=8) or without urate (PN, 
n=10). The PN containing syringes were covered with foil to protect the solution against 
photo-degradation. There were two control groups, in which pH 8.4 saline (C1; n=14) or urate 
(UAC; n=9) were given prior to the prolonged I/R insult. 
In five additional groups the hearts were stopped after two periods of saline (pH 8.4, C2; n=4) 
or PN infusions (PN; n=3), or the PC occlusion/reperfusion insults (PC; n=4) in the absence 
of UA and also in the presence of urate (UA+PC; n=3; UA+PN; n=3). In these myocardial 
samples the formation of NT was assessed. In those animals that were underwent prolonged 
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ischaemia and were alive 2 min after reperfusion, the hearts were stopped with an excess of 
anaesthetic and tissue samples were taken from the ischaemic myocardial wall for the 
determination of superoxide and NT. 
 
 
 
 
2.6.2. Protocol for Study II. This is illustrated in Figure 2. In this study dogs were selected 
randomly to form seven groups, each containing from 3 to 5 animals. After surgery, the dogs 
were allowed to recover for 30 min. In all groups, except the sham-operated controls, 
myocardial ischaemia was induced by the occlusion of the LAD. Three groups served as 
controls. In these groups after euthanasia with an excess of the anaesthetic, myocardial tissue 
samples were collected either at the end of the 30 min recovery period (C0; n=5) or at 5 min 
(C1; n=4) and 25 min (C2; n=3) of the coronary artery occlusion. In four groups, the dogs 
were preconditioned by two 5 min occlusion of the LAD interspersed with a 5 min 
Figure 1. Experimental protocol to examine the trigger role of PN in cardioprotection 
induced by ischaemic PC and by the administration of PN. 
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reperfusion interval. In these groups after stopping the heart by the administration of an 
overdose of the anaesthetic, samples were taken either at the end (PC1; n=5) or 5 min after 
(PC2; n=4) of the second PC occlusion, as well as also at the 5 min (PC3; n=4) and 25 min 
(PC4; n=3) of the prolonged ischaemia. In each group tissue samples for the determination of 
NOS activity and superoxide production were excised from the ischaemic area supplied by the 
occluded LAD. Blood samples (BS) were also taken from the coronary sinus at various time 
points of the experiments to measure plasma NOx levels. 
 
 
 
 
 
 
 
 
 
Figure 2. Experimental protocol for the examination of the time-dependent changes in NOS 
enzyme activity, NOx concentrations, as well as superoxide and nitrotyrosine productions in 
control and in preconditioned dogs.  
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3. RESULTS 
3.1. Study I. Evaluation of the trigger role of peroxynitrite in the antiarrhythmic effect 
of ischaemic preconditioning 
3.1.1. Haemodynamic effects of pH 8.4 saline, peroxynitrite and urate  
These are summarised in Table 1. None of the infusion of pH 8.4 saline, peroxynitrite and uric 
acid caused significant alterations in the haemodynamic parameters.  
Table 1. Haemodynamic effects of pH 8.4 saline, urate and peroxynitrite 
 
 
 
 
3.1.2. Haemodynamic changes following coronary artery occlusion  
These are illustrated in Table 2. In all groups, occlusion of the LAD resulted in significant 
decreases in arterial blood pressure, LVSP, positive and negative dP/dtmax and an increase in 
LVEDP. These haemodynamic changes were, however, significantly less both in the PC and 
the PN treated animals. Although UA itself did not influence either the ischaemia or the PC-
induced haemodynamic changes, it abolished the effects of PN infusion in these parameters. 
In anaesthetized dogs, coronary artery occlusion did not substantially modify heart rate.  
Data are presented as changes, measured 5 min after starting the infusions. Abbreviations: 
SABP, systolic arterial blood pressure; DABP, diastolic arterial blood pressure; MABP, 
mean arterial blood pressure; LVSP, left ventricular systolic pressure; LVEDP, left 
ventricular end-diastolic pressure; HR, heart rate. Data are means ± s.e.m. 
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Haemodynamic 
parameters 
Control PC PN UAC UA+PC UA+PN 
Baseline 
Max. 
change 
Baseline 
Max. 
change 
Baseline 
Max. 
change 
Baseline 
Max. 
change 
Baseline 
Max. 
change 
Baseline 
Max. 
change 
SABP (mmHg) 128 ± 6 -17 ± 1a 122 ± 5 -10 ± 1ab 125 ± 6 -11 ± 1ab 133 ± 3 -13 ± 1a 121 ± 7 -13 ± 3ab 128 ± 3 -13 ± 3a 
DABP (mmHg) 85 ± 4 -15 ± 1a 84 ± 3 -10 ± 1ab 85 ± 4 -9 ± 2ab 87 ± 3 -13 ± 3a 81 ± 5 -10 ± 2ab 89 ± 1 -15 ± 5a 
MABP (mmHg) 99 ± 5 -16 ± 2a 97 ± 4 -10 ± 1ab 98 ± 5 -10 ± 1ab 102 ± 3 -13 ± 2a 95 ± 5 -12 ± 3ab 102 ± 2 -14 ± 4a 
LVSP (mmHg) 127 ± 5 -18 ± 2a 112 ± 5 -11 ± 11ab 127 ± 6 -13 ± 2ab 128 ± 4 -18 ± 5a 124 ± 6 -12 ± 2ab 129 ± 2 -15 ± 3a 
LVEDP (mmHg) 3.8 ± 0.4 8.0 ± 0.8a 3.9 ± 0.4 5.3 ± 0.1ab 3.4 ± 0.4 5.0 ± 0.5ab 2.8 ± 0.4 7 ± 1a 3.6 ± 0.3 6.5 ± 0.8a 3.4 ± 0.5 7.8 ± 1.4a 
+dP/dtmax (mmHg∙s
-1
) 2780 ± 132 -558 ± 100a 2441 ± 180 -380 ± 51ab 2742 ± 168 -439 ± 53a 2880 ± 170 -516 ± 79a 2575 ± 52 -380 ± 72ab 2564 ± 172 -658 ± 126a 
-dP/dtmax (mmHg∙s
-1
) 2086 ± 72 -611 ± 83a 1998 ± 146 -276 ± 49ab 1868 ± 83 -326 ± 50ab 2209 ± 68 -583 ± 103a 2110 ± 52 -133 ± 43ab 2065 ± 107 -568 ± 114a 
HR (beats∙min
-1
) 154 ± 3 1 ± 2 140 ± 6 1 ± 3 150 ± 7 2 ± 2 152 ± 9 2 ± 2 160 ± 7 -1 ± 1 155 ± 5 3 ± 2 
Abbreviations: SABP, systolic arterial blood pressure; DABP, diastolic arterial blood pressure; MABP, mean arterial blood pressure; LVSP, left 
ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; HR, heart rate. Data are means ± s.e.m., bP<0.05 compared to the 
control and 
a
P<0.05 compared to the baseline value. 
Table 2. Haemodynamic changes during a 25 min occlusion of the LAD  
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3.1.3. The severity of ventricular arrhythmias during a 25 min occlusion of the LAD 
These are illustrated in Figures 3 and 4. Occlusion of the LAD for 25 min resulted in high 
number of VPBs (289 ± 74) and many episodes of VT (11.0 ± 3.6) that occurred in 93% of the 
control dogs (Figure 3). Furthermore, in this group VF was apparent in 50% of the animals 
during the occlusion, and no dog survived the combined occlusion and reperfusion insult 
(Figure 4).  
 
 
Both PC and the infusion of PN significantly decreased the severity of the ischaemia-induced 
ventricular arrhythmias and increased survival following reperfusion (Figures 3 and 4). 
Interestingly, the administration of UA did not influence the antiarrhythmic effects of PC, but 
almost completely abolished the PN-induced protection. Thus, survival from the combined 
I/R insult was similar in the PC dogs, no matter whether UA was given or not (63% vs. 60 %, 
respectively), whereas in the PN-treated dogs, in the presence of UA, survival reduced from 
50% to 25%. Surprisingly, UA itself also resulted in protection against the acute I/R-induced 
Figure 3. The total number of VPBs, the incidence and the number of episodes of VT 
during a 25 min coronary artery occlusion in control, preconditioned and peroxynitrite 
treated dogs, both in the presence (UA, UA+PC, UA+PN) and in the absence of UA (C1, 
PC, PN). Values are means ± s.e.m., *P<0.05 vs. C1. 
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ventricular arrhythmias. Compared with controls, in dogs given UA alone there were less 
numbers of ectopic beats (50 ± 14) and episodes of VT (0.3 ± 0.3), as well as lower 
incidences of VT (11%) and VF (0%) during the occlusion, and survival was increased from 
0% to 55%. 
 
 
3.1.4. Changes in ischaemia severity during a 25 min occlusion of the LAD 
This was assessed by two parameters; i.e. changes in epicardial ST-segment (Figure 5A) and 
in the degree of inhomogeneity of electrical activation (Figure 5B). In control dogs occlusion 
of the LAD resulted in significant increases in both the epicardial ST-segment and the degree 
of inhomogeneity, which were especially pronounced during the first 5 min of the occlusion. 
In contrast, these indices of ischaemia severity were significantly less pronounced in the PC 
and in the PN-treated dogs. Whereas in PC dogs the administration of UA did not 
substantially modify the epicardial ST-segment changes and the degree of inhomogeneity, in 
the PN-treated dogs the anti-ischaemic effects were abolished by UA. Uric acid given alone 
also exhibited an anti-ischaemic effect. 
Figure 4. The incidence of VF during occlusion and reperfusion, as well as survival 
from the combined I/R insult. Values are means ± s.e.m., *P<0.05 vs. C1. 
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3.1.5. Changes in plasma NOx concentrations during a 25 min occlusion of the LAD 
There were no significant differences among the groups in the baseline plasma levels of NOx 
(Figure 6). Both the PC occlusions and also the similar periods of PN infusion increased the 
level of NO metabolites (Figure 6A), and this was maintained over the entire prolonged 
period of ischaemia (Figure 6B). This was in contrast with the control dogs, in which NOx 
levels were markedly reduced by the end of occlusion period (Figure 6B). Uric acid given 
alone did not influence NOx levels either before or during the sustained ischaemia, and it also 
failed to modify NO bioavailability in the PC dogs. Uric acid, however, abolished the PN-
induced increase in NOx both prior to and during the 25 min of the occlusion. 
 
Figure 5. Changes in the epicardial ST-segment (A) and in the degree of inhomogeneity of 
electrical activation (B) during a 25 min occlusion of the LAD. Values are means ± s.e.m., 
*P<0.05 vs. C1 and 
#
P<0.05 vs. baseline. 
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3.1.6. Myocardial superoxide production following a 25 min occlusion and reperfusion 
Myocardial superoxide production was determined 2 min after reperfusion (Figure 7). 
Compared with the sham controls (C2) a 25 min I/R insult markedly elevated superoxide 
production, which was significantly attenuated by PC and the administration of PN. Urate 
itself also decreased the generation of ROS and abolished the PN-induced reduction in ROS 
formation. Urate, however, did not modify the effect of PC on superoxide production. 
 
 
Figure 6. Plasma NOx levels after PC and infusion of PN, as well as following a 25 min 
LAD occlusion (shaded bars). Values are means ± s.e.m., *P<0.05 vs. C1, and #P<0.05 vs. 
baseline and/pre-occlusion values. 
Figure 7. Changes in superoxide production, after a 25 min I/R insult in control (C1) 
preconditioned (PC) and PN treated dogs in the absence and in the presence of UA (UAC, 
UA+PC, UA+PN).Values are means ± s.e.m., *P<0.05 vs. C1 and #P<0.05 vs. C2. 
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3.1.7. Changes in myocardial nitrotyrosine production 
This was determined in tissue samples both after the application of PC and PN (Figure 8A) 
and following the prolonged I/R insult (Figure 8B). Compared with the saline infused controls 
(C2), both PC and the infusion of PN significantly increased myocardial NT formation. This 
effect was abolished in the presence of UA (Figure 8A). Occlusion and reperfusion of the 
LAD for 25 min markedly increased NT production, which was significantly less marked both 
in the PC and the PN-treated animals. Although UA itself reduced NT formation that resulted 
from a prolonged period of I/R, it only abolished the effect of PN on NT production (Figure 
8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Myocardial nitrotyrosine formation following PC and the infusion of PN 
infusion, as well as a 25 min occlusion of LAD. Values are means ± s.e.m., *P<0.05 
vs. C1 or C2 control groups. 
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3.2. Study II. Examination of changes in NOS activity during myocardial ischaemia 
The objective of this study was to examine, whether changes in the plasma concentrations of 
NO metabolites (nitrate and nitrite) during coronary artery occlusion are due to a time-course 
alteration in NOS activity.   
3.2.1. NOS enzyme activity following PC and a prolonged period of LAD occlusion 
The changes in NOS activation are illustrated in Figure 9. Compared to the sham controls 
(C0), in dogs subjected to ischaemia there was a marked increase in NOS activity occurring in 
samples taken 5 min after the onset of the occlusion (C1). However, when the ischaemia was 
maintained for 25 min, the activation of NOS was markedly reduced by the end of the 
occlusion period (C2). The PC procedure (two 5 min occlusions with a 5 min reperfusion 
interval in between) itself increased the activity of NOS (PC1), but this returned to normal 5 
min later (PC2). In these PC dogs, however, the NOS enzyme was rapidly activated again, 
when the animals were subjected to prolonged ischaemia, and this activation continued over 
the entire 25 min occlusion period (PC4). 
 
 
 
Figure 9. Time course changes in total NOS activity in control and in preconditioned 
dogs. Values are means ± s.e.m., *P<0.05 vs. C2 and  #P<0.05 vs. C0. 
36 
 
 
3.2.2. Changes in plasma nitrate/nitrite (NOx) levels following preconditioning and during 
sustained ischaemia  
The NOx levels changed almost parallel with the activation of NOS (Figure 10). The baseline 
plasma level of NO metabolites in the blood of the coronary sinus was 20.3 ± 0.1 µmol/L 
(data obtained at this time point [C0] from control and PC dogs, were summed). In control 
dogs, occlusion of the LAD resulted in a significant increase in NOx that occurred in samples 
taken at 7 min of ischaemia (C1). After this, the concentration of the NO metabolites started 
to decline, and by the end of the 25 min occlusion (C2), it became significantly lower than the 
initial baseline value. In contrast, NOx levels elevated following the PC procedure (PC1 and 
PC2), and these were maintained or even further increased during the subsequent prolonged 
period of the occlusion (PC3 and PC4).   
 
 
 
 
 
 
Figure 10. Time course changes in plasma nitrate/nitrite (NOx) concentrations in 
control and in preconditioned dogs. Values are means ± s.e.m., *P<0.05 vs. C2 group 
and 
#
P<0.05 vs. C0 group. 
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3.2.3. Changes in myocardial superoxide production following the PC procedure and 
during a 25 min LAD occlusion  
Compared to the sham controls, the production of superoxide was significantly increased in 
dogs that had been subjected to a 25 min occlusion (C2). This result indicates that a marked 
generation of ROS may occur already during the later period of the ischaemia (Figure 11). 
Although the PC procedure itself increased the generation of superoxide (PC1 and PC2), the 
superoxide production was less pronounced during the prolonged occlusion in these dogs than 
in the controls (C2 compared with PC4; P<0.05).  
 
 
 
 
 
 
  
 
Figure 11. Myocardial superoxide production in control and in preconditioned 
dogs. Values are means ± s.e.m., #P<0.05 vs. C0 group and *P<0.05 vs. C2 group. 
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3.2.4. Changes in nitrotyrosine formation in control and in preconditioned dogs 
 For the assessment of peroxynitrite formation, the generation of nitrotyrosine was determined 
in myocardial tissue samples taken at various time points from control and PC dogs (Figure 
12). Compared with the sham controls, occlusion of the LAD significantly increased NT 
formation (C0 compared with C2; P<0.05). There was also an enhanced NT production 
following the PC procedure (C0 compared with PC1 and PC2; P<0.05), but the amount of this 
stable product of NO and superoxide reaction was not substantially changed during the  
subsequent, more prolonged period of occlusion (PC2 compared with PC3 and PC4; ns), nor 
significantly different from that obtained in the controls (C2 compared with PC4; ns). 
 
 
 
 
 
 
 
 
 
Figure 12. Nitrotyrosine formation in control and in preconditioned dogs. Values 
are means ± s.e.m., #P<0.05 vs. C0 group. 
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4. DISCUSSION 
New findings 
Study I. 
1. We have demonstrated that peroxynitrite is produced during preconditioning, induced by 
brief periods of ischaemia and reperfusion insults. This peroxynitrite formation, however, 
most probably does not play an important role in the induction of the antiarrhythmic effect 
of preconditioning, since the protection is still present, if peroxynitrite is scavenged by uric 
acid, during the PC procedure. 
2. In contrast, the cardioprotective effects of the exogenously applied peroxynitrite are 
completely abolished by the administration of urate.  
3. We have also pointed out that uric acid itself may provide an antiarrhythmic effect. This 
effect may be associated with the antioxidant properties of urate. 
Thus our conclusion from Study I is that although peroxynitrite in low (100 nM) 
concentration can induce a preconditioning-like antiarrhythmic protection, the endogenously 
formed peroxynitrite is not necessary for the initiation of the PC-induced protection against 
arrhythmias.   
Study II. 
The results of this study provided evidence that NO bioavailability during a prolonged (25 
min) coronary artery occlusion is tightly associated with the function of NOS enzyme. This 
observation is supported by the facts that 
(i) a prolonged period of ischaemia decreases the activity of NOS (perhaps by uncoupling of 
the enzyme), resulting in reduced NO and increased superoxide and nitrotyrosine 
productions, 
(ii) preconditioning results in rapid activation of NOS, and this increase in NOS activity 
persists during the subsequent more prolonged period of ischaemia, resulting in better NO 
bioavailability and suppressed oxygen radical productions. We suggest that these effects 
are certainly playing a role in the antiarrhythmic effect of PC.  
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The findings, summarized in the present thesis, result from two separate studies. 
In Study I, which aimed to examine the trigger role of PN in the antiarrhythmic effects of PC 
and PN infusion, we confirmed our previous results that the administration of the nanomolar 
concentration of peroxynitrite directly into the coronary circulation results in similar 
antiarrhythmic effect that can be achieved with ischaemic preconditioning (Kiss et al., 2010). 
This protection is manifested not only in a reduction in the severity of arrhythmias, but also in 
an attenuation of ischaemic changes, preservation in NO bioavailability during ischaemia and 
suppression of oxidative stress products, mainly superoxide, during the early phase of the 
reperfusion. Since there is some evidence that during the short periods of ischaemia and 
reperfusion insults (i.e. preconditioning), peroxynitrite may be generated from the reaction of 
NO and superoxide (Altug et al., 2000, 2001), we have raised the question whether in our 
canine model, PN can be formed in sufficient concentration during the PC stimulus, to trigger 
and thereby contribute to the antiarrhythmic protection. Therefore, we designed studies in 
which uric acid (UA), a relatively selective scavenger of PN was infused prior to and during 
the PC protocol and also the infusion of PN. We have found that in the presence of UA, 
although both the PC and the exogenous PN-induced increase in NT formation was abolished, 
the antiarrhythmic effect that resulted from PC remained to be unaffected. This was in 
contrast with the protection resulted from PN infusion; here scavenging of the exogenously 
administrated PN by urate, the antiarrhythmic and the other cardioprotective (anti-ischaemic, 
NO preserving, superoxide suppressing, etc.) effects were completely abolished. Thus, we 
conclude that although PN can induce cardioprotection, and that PN is generated during the 
PC procedure, this endogenously formed PN is not necessary for the induction of the PC-
evoked cardioprotective (antiarrhythmic) effects. 
Despite the similarities between the PC and PN-induced protection, there might be 
dissimilarities as well, in particular as regards the underlying mechanisms. For example, in 
this canine model it has been found previously that mitoKATP channels play a role in the 
antiarrhythmic effect of PC, since the protection was abolished by the mitoKATP channel 
blocker 5-hydroxydecanoate (Végh et al., 2002). In contrast, in the same model, 5-HD failed 
to inhibit the antiarrhythmic protection, resulted from exogenous PN administration (Kiss et 
al., 2008). It might well be that there are differences between PC and the application of PN 
regarding the signalization that lead to cardioprotection. For example, it has been shown that 
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PN can directly activate downstream targets of PC signalling pathways, including protein 
kinase C (Agbani et al., 2011). There might be also species differences that would explain the 
divergent results. In this respect the studies of Altug and colleagues (Altug et al., 2001) are 
particularly interesting. They showed that in the rat isolated heart preparations, uric acid 
abolished both the PC and the PN-induced cardioprotective effects (Altug et al., 2001), from 
which they concluded that PN can serve as a trigger for PC. In this study, however, neither the 
generation of NO, nor the production of superoxide and peroxynitrite were determined. 
One explanation for the difference might be related to the strength of the PC stimulus used in 
the various experimental setting; i.e. whether a certain PC protocol is able to provide 
sufficient stimulus for the formation of endogenous PN. One of our previous studies (Hajnal 
et al., 2004) showed that in anaesthetized dogs a single 5 min period of occlusion/reperfusion 
was insufficient to produce detectable changes in superoxide production. In this model at least 
two 5 min PC cycles had to be applied in order to obtain a detectable increase in blood 
superoxide concentration (Hajnal et al., 2004). It is also likely that the PC procedure not only 
generates ROS, but stimulates the free radical scavenging systems, such as the activity of 
manganese superoxide dismutase (Hoshida et al., 1993) as well. This may also account for the 
rapid elimination of superoxide formation, in particular, if the strength of the PC stimulus is 
not strong enough. 
Whatever supposition is true, it seems from our studies that the two 5 min period occlusion 
and reperfusion insults that we used for preconditioning, stimulates the generation of NO and 
also of superoxide (Kiss et al., 2010), thus it is more than likely that these radicals react and 
form peroxynitrite. Indeed, our Study II provided an evidence for this, showing that the two 5 
min occlusion/reperfusion insults increased myocardial nitrotyrosine levels (Figure 12). 
Nevertheless, uric acid, a scavenger of PN failed to modify the antiarrhythmic and the anti-
ischaemic effects of PC. In contrast, urate completely abolished the protective effects that 
resulted from PN administration. Therefore, we think that in our canine model, the 
endogenous PN formation does not play a pivotal role in the antiarrhythmic effect of 
ischaemic PC. 
We propose that in this model of ischaemia/reperfusion, other substances that are generated 
and released during the PC procedure may play a more essential role. The most likely 
candidate for this is nitric oxide. We have a surmountable amount of evidence that NO plays 
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an important trigger and mediator role in PC, induced either by brief coronary artery 
occlusions (Végh et al., 1992b; Végh and Parratt, 1996), cardiac pacing (Kis et al., 1999a,b) 
or heavy physical exercise (Babai et al., 2002). 
There is also evidence that NO, among the other effects, plays an important role in the 
regulation of superoxide production that occurs after a prolonged period of ischaemia and 
reperfusion insult (Kiss et al., 2010). This effect can explain that both myocardial superoxide 
and NT formation were markedly reduced in the PC dogs, but also in dogs that had been 
given PN exogenously. However, urate in a dose of 0.2 mg/kg/min only abolished the effects 
of the exogenously administered PN without substantially modifying the superoxide and NT 
reducing effects of PC. We suppose that the loss of the PN-induced protection is largely due to 
the fact that PN has been scavenged by UA already during the infusion period. 
To evaluate the selectivity of urate for peroxynitrite, especially under in vivo conditions, is 
rather difficult. The production of endogenous PN can only be indirectly assessed by 
measuring nitrotyrosine, which is a stable product of the reaction between PN and tyrosine 
residues of proteins. Nitrotyrosine is generally accepted as a biomarker of endogenous PN 
formation (Skinner et al., 1998). Nevertheless, it is also likely, that PN is not the solely 
substrate of UA (Teng et al., 2002; Squadrito et al., 2000). This assumption is supported by 
the results which showed that when UA had been given alone prior to a 25 min occlusion and 
reperfusion, there was also a marked reduction in superoxide production (Figure 7). There are 
of course, a number of other possible scavengers, such as ebselen (Parnham and Siesh, 2000) 
and metalloporhyrins (Crow, 1999; Klassen and Rabkin, 2009; Daiber et al., 2000), which 
could have been used in our experiments, but these scavengers are also not selective and 
specific for PN; they can inhibit a wide range of enzymes or interact with other bio-molecules 
(Crow, 1999; Ferdinandy et al., 2000; Lauzier et al., 2007). 
Interestingly UA alone, administered prior to a prolonged period of I/R insult provided 
protection against arrhythmias and reduced the formation of the reperfusion induced oxidative 
and nitrosative stress products. Although the precise mechanism by which urate exerts 
protection is not fully elaborated, it is likely that such a protective effect can be associated 
with the antioxidant properties of urate. There is well documented in the literature, that the 
endogenously formed urate accounts for approximately 60 % of plasma total antioxidant 
capacity (Ames et al., 1981; Robinson et al., 2004), since it is able to react with different 
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oxygen derived free radicals, such as singlet oxygen, hydroxyl radical, oxo-heme oxidants 
(Ames et al., 1981), as well as peroxyl radicals (Robinson et al., 2004). Furthermore, urate is 
widely used for scavenging NO-derived free radicals, such as peroxynitrite, generated either 
endogenously or administered exogenously (Kooy et al., 1994; Skinner et al., 1998; Altug et 
al., 2001; Kuzkaya et al., 2003, 2005). It can also trap peroxynitrous acid, the decomposition 
product of peroxynitrite (Santos et al., 1999).  
In summary, the results of Study I demonstrated that the exogenously administered PN can 
provide similar protection against the ischaemia and reperfusion-induced severe ventricular 
arrhythmias that can be observed with ischaemic PC. This PN-induced protection was, 
however, abolished by the simultaneous administration of uric acid. In contrast, although the 
PC procedure induces endogenous PN formation, the antiarrhythmic effect of PC was not 
substantially modified by the PN scavenger urate. These results strongly indicate that the 
endogenously generated PN from the PC stimulus is not required for the development of PC-
induced protection.                  
In Study II we aimed to examine whether the increase in NO bioavailability during ischaemia 
in PC dogs is due to a NOS-dependent or a NOS-independent mechanism. 
We stared from those previous observations that in dogs subjected to a 25 min coronary artery 
occlusion and reperfusion, the concentration of NO, assessed by measuring plasma 
nitrate/nitrite levels in the blood of the coronary sinus, changed in a biphasic manner; i.e. 
there was an apparent increase in NOx that occurred soon after (around 7 min) the 
commencement of the occlusion, followed by a continuous decrease up to the end of the 25 
min period of ischaemia (Kiss et al., 2010). In this study we have also pointed out that in dogs 
subjected to PC the NOx levels were preserved over the entire prolonged period of occlusion 
(Kiss et al., 2010). Since in this study NOS enzyme activity was not measured, we designed 
experiments in which primarily the activity of NOS was assessed in parallel with changes in 
plasma NOx, as well as myocardial superoxide and NT levels in control and in PC dogs. 
The results show that total NOS activity was significantly increased following a 5 min period 
of coronary artery occlusion (Figure 9; C1), indicating a rapid NOS activation and NO 
formation (Figure 10; C1) following ischaemia. This finding well accords with those previous 
observations, which suggested that ischaemia rapidly activates NOS (Depré et al., 1997), due 
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to the changes in cytosolic calcium levels and enzyme phosphorylation (Govers and Rabelink, 
2001). In contrast, if the ischaemia was maintained for 25 min, the activity of NOS started to 
decrease, and there was a parallel reduction in the plasma NOx levels (Figure 9 and 10; C2). 
Thus it seems likely that the decrease in NO bioavailability during a prolonged occlusion can 
be associated with a reduction in NOS activation, but it cannot be ruled out that the formation 
of peroxynitrite, resulting from the combination of NO with superoxide, may also play a role. 
Indeed, the present study clearly demonstrated that in control samples both the superoxide and 
NT levels were markedly elevated by the end of the sustained ischaemia (Figure 11 and 12; 
C2), confirming those previous findings, which showed that superoxide can be generated even 
during ischaemia (Vanden Hoek et al., 1997; Becker et al., 1999), especially when the NOS 
enzyme uncouples because of the limited supply of oxygen, substrate and cofactors. This 
uncoupling would lead to decreased NO and, in parallel, increased superoxide production by 
NOS (Xia et al., 1998; Dumitrescu et al., 2007).  
The present study also showed that PC stimulates NOS; but interestingly the activity of NOS 
following the two 5 min occlusions (PC1 group) was not as marked as that could be observed 
after a single 5 min occlusion (C1 group). An explanation for this difference in NOS activity 
between these groups may lie in the reperfusion interval, which elapses between the first and 
the second PC occlusions, suggesting that the NOS enzyme is not only rapidly activated by 
ischaemia (Depré et al., 1997), but it can also rapidly be deactivated when the ischaemia 
ceases. This assumption is confirmed by the results obtained from samples of PC2 dogs. 
These clearly show that NOS activity returned to the normal value after 5 min of the release 
of the second PC occlusion. Interestingly, despite this decrease in NOS activation, the plasma 
NOx seems to be maintained over the entire PC procedure. There was also an apparent 
increase in superoxide and nitrotyrosine production during the consecutive 5 min periods of 
preconditioning occlusion and reperfusion insults, supporting the role of these nitrogen and 
oxygen radicals in the initiation of the PC-induced protection (Végh et al., 1992b; Tanaka et 
al., 1994; Pain et al., 2000; Ferdinandy and Schulz 2003). 
We assume these radicals generated during the PC procedure may have also a regulatory 
effect on NOS activity, whereby they contribute to the normalization of NOS activity soon 
after the release of the second PC occlusion. Indeed, studies, examining endothelial NOS 
activity and NO bioavailability in relation to normal and impaired vascular function (Govers 
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and Rabelink, 2001; Harrison 1997; Peterson et al., 1999; Guzik et al., 2002; Chen et al., 
2008), have revealed that the ischaemia and reperfusion-induced free radical products by 
acting on various regulatory domains of NOS, are able to modify NOS activity in order to 
keep the balance between NO and superoxide production (Stuehr et al., 2004; Chatterjee and 
Catravas, 2008). For example, it has been shown that an excess in superoxide production 
would deactivate NOS, resulting in reduced free NO levels and subsequent peroxynitrite 
formation (Yaqoob et al., 1996). Similarly, under certain conditions the excessively generated 
NO can regulate, through a negative feedback (auto-inhibitory) mechanism the subsequent 
enzymatic synthesis of NO (Rengasamy and Johns 1993; Kotsonis et al., 1999, 2000). As to 
whether in our experimental circumstances these radicals are, indeed, involved in the 
regulation of NOS is not known, what is certain that 5 min after the release of the second PC 
occlusion the activity of NOS has returned to the normal value, whereas the concentration of 
NO, superoxide and nitrotyrosine is remained to be still elevated.  
When the PC dogs were subjected again to occlusion (5 min or 25 min), the activity of NOS 
and simultaneously, the NOx levels were rapidly increased (PC3 group), but, in contrast to the 
controls, these were maintained or even further increased by the end of the 25 min occlusion 
(Figure 9 and 10; C2 compared with PC4; P<0.05). Conversely, the superoxide production 
during the prolonged occlusion was substantially less marked in the PC dogs than in the 
controls (Figure 11), whereas such a reduction in the NT production was not apparent (Figure 
12). The reason for this might be that since NT is a stable product, the NT production 
determined at the end of the prolonged ischaemia, has already contained the amount of the 
previously formed peroxynitrite as well. Nevertheless, our results, obtained from the parallel 
measurement of NOS activation and products, which is an advantage of this study, clearly 
demonstrated that PC preserves the function of NOS and, as a result of it, increases NO 
bioavailability and decreases superoxide production during a subsequent prolonged period of 
occlusion. This finding confirms the previous observations in rat isolated hearts that PC 
prevents the loss of NOS enzymes and enhances NOS activity during ischaemia and 
reperfusion (Muscari et al., 2004).       
There is some evidence coming mainly from in vitro studies that phosphorylation of NOS at 
various sites can rapidly modify NOS activity (Mount et al., 2007). For example, it has just 
recently been reported that in isolated rat hearts, PC, through the stimulation of the Akt-PKA 
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pathway, activates eNOS via serine 1176 phosphorylation (Yang et al., 2013). Also, post-
translational modifications, such as protein-protein interactions, have been suggested as 
important mechanisms in NOS regulation (Gratton et al., 2000). Despite all attempts, the 
precise mechanism by which PC preserves the function of NOS has not yet been fully 
elucidated and, indeed, it was not the objective of the present study either. The main focus of 
this study was a systematic evaluation of NOS activation with a simultaneous measurement 
its products during ischaemia and following PC in an in vivo large animal model. Considering 
the data of our own and of the others, we can speculate that PC perhaps by preventing the 
uncoupling of NOS during ischaemia would influence the function of the enzyme. It is well 
known that NOS primary produces NO in the presence of adequate supply of substrate and 
cofactors, such as tetrahydrobiopterin (BH4), NADPH, FAD and flavin mononucleotide 
(Cosentino and Lüscher, 1999). Among these BH4 seems to be an essential cofactor for NOS 
to produce NO (Xia et al., 1998) by stabilizing NOS dimmers (reductase and oxygenase 
domains; Moens and Kass, 2006), increasing substrate affinity to the enzyme (Kotsonis et al., 
2000) and inhibiting NOS-mediated superoxide production (Xia et al., 1998). There is also 
evidence that under ischaemic conditions the bioavailability of BH4 is reduced and this, rather 
than the inadequate substrate availability (Chatterjee and Catravas, 2008), results in 
uncoupling of NOS leading to superoxide rather than to NO production (Vasquez-Vivar et al., 
1998). Indeed, it has been found that in diseases associated with impaired endothelial 
function, such as hypertension, diabetes, etc., the supplementation of BH4 improved 
endothelial function (Heitzer et al., 2000). Furthermore, in anaesthetized rabbits, PC 
decreased infarct size and increased BH4 concentrations after a 30 min coronary artery 
occlusion (Vladic et al., 2011), which suggests that PC by elevating BH4 levels prevents the 
uncoupling of NOS and preserves the function of NOS to produce NO even during a 
prolonged ischaemic period. Although in the present study the concentrations of BH4 were 
not determined, it is reasonable to hypothesise that a similar mechanism may play a role in 
our dog model. If so, then this would certainly explain the observed increase in NOS activity 
and NO synthesis, as well as the decrease in superoxide production in the PC dogs compared 
with controls.  
In summary, the results of Study II demonstrate that in anaesthetized dogs, a short period of 
ischaemia rapidly activates the NOS enzyme and results in increased NO generation. In 
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contrast, a longer period of ischaemia decreases NOS activity and the NO bioavailability, with 
a parallel increase in superoxide and peroxynitrite production. This effect may associate with 
the uncoupling of NOS, although in the decrease of NO, the formation of peroxynitrite may 
also play a role. This study also shows that PC induced by brief occlusion and reperfusion 
insults enhances NOS activity and NO synthesis, but it also elevates the production of ROS; 
all these radicals are thought to play a trigger role in the PC–induced protection. Although we 
do not know how these radicals, generated during the PC procedure, modify NOS activity, 
what is certain, PC preserves the function of NOS, during prolonged occlusion and results in 
enhanced NO and suppressed superoxide production. We assume that in our model this 
mechanism plays an important role in the antiarrhythmic effects of PC.                 
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